Baxter(US:BAX)2026-02-12 21:46Research and Development - R&D expenditures were $518 million in 2025, $590 million in 2024, and $518 million in 2023, focusing on enhancing future growth through clinical differentiation [43]. - The company aims to create a more resilient supply chain and align its manufacturing footprint with commercial activities, potentially consolidating R&D facilities [43]. Workforce and Employee Engagement - The company employed approximately 37,500 people globally as of December 31, 2025, with 15,100 employees in the United States and 22,400 employees outside the United States [52]. - Recruitment efforts include a tuition reimbursement program and an e-learning platform, BaxU, to foster a growth mindset among employees [55]. - The company conducts anonymous surveys to assess employee feedback on leadership confidence, compensation competitiveness, and career growth opportunities [55]. - The results of employee engagement surveys are reviewed by senior leaders and shared with the Board of Directors [55]. - The company is committed to improving its human resources programs based on survey feedback from its global workforce [55]. - The company emphasizes a zero-harm workplace and is focused on employee engagement and safety controls for high hazard work activities [55]. - The company’s compensation programs are designed to align employee compensation with performance, balancing short-term and long-term incentives [55]. Business Strategy and Portfolio Management - The company is actively managing its portfolio through acquisitions and divestitures, including the divestiture of its Kidney Care business [32]. - The company has established purchasing agreements with several major Group Purchasing Organizations (GPOs) in the United States, which are subject to renewal [34]. Regulatory and Legal Environment - The company is subject to extensive regulation by various government agencies, including the FDA and EMA, impacting product testing, safety, and marketing [49]. - The company is involved in ongoing patent litigation, which can result in significant financial implications and affect product sales [42]. - The company faces risks related to patent protection and potential litigation that could impact competitiveness and business prospects [334]. Financial Performance and Market Conditions - The company has decreased its quarterly dividend to $0.01 per share and cannot guarantee future increases or continuity in dividend payments [334]. - The company’s stock price has experienced significant fluctuations and may continue to do so [334]. - Changes in tax laws may negatively affect the company's operating results [334]. Competition and Market Position - The company faces substantial competition in each of its segments from both international and domestic healthcare and medical product companies [38]. Sustainability and Corporate Responsibility - The company is focused on sustainability and corporate responsibility, with a 2030 Corporate Responsibility Commitment anchored by three strategic goals [48].